OBJECTIVE: This study was conducted to determine the association between the use of injectable progestin contraception (IPC) and the risk of infection with Neisseria gonorrhoeae (GC), Chlamydia trachomatis (CT), bacterial vaginosis (BV) and Trichomonas vaginalis (TV) among women in South Africa. METHODS: From August 1999 through May 2001, 643 HIV-1-negative women were recruited from family planning clinics in Orange Farm, South Africa. IPC [norethisterone enanthate (NET-EN) and depot medroxyprogesterone acetate (DMPA)] users and nonhormonal contraception users were recruited in approximately equal numbers. Eligible participants were seen at enrolment and on four follow-up visits over a 12-month period; 567 returned for at least one follow-up visit. Multivariable Poisson regression models with generalized estimating equations were used to compute the incidence rate ratios (IRRs) for infections with GC, CT, BV and TV by use of NET-EN or DMPA relative to nonuse during follow-up. RESULTS: In multivariable models, the use of DMPA slightly increased the risk of infection with CT [IRR=1.24; 95% confidence interval (95% CI)=0.80-1.94] and GC (IRR=1.30; 95% CI=0.58-2.98), although these associations were not statistically significant. In contrast, DMPA appeared to be protective for TV (IRR=0.35; 95% CI=0.12-1.01), although this estimate was very imprecise. The use of both DMPA and NET-EN was associated with a decreased risk of BV. CONCLUSIONS: The use of DMPA among women in this study population was associated with an increased - but not statistically significant - risk of cervical infection with chlamydia and gonorrhea, and a decreased risk of TV and BV. Given the inconsistencies and limitations of the data describing an increased risk of CT and GC with IPC use, the potential risk of sexually transmitted infections (STIs) must be balanced against the risk of unintended pregnancy and its health consequences, especially in developing countries. Women opting to use IPC should be counseled to use condoms to protect against STIs and HIV.
OBJECTIVE: This study was conducted to determine the association between the use of injectable progestin contraception (IPC) and the risk of infection with Neisseria gonorrhoeae (GC), Chlamydia trachomatis (CT), bacterial vaginosis (BV) and Trichomonas vaginalis (TV) among women in South Africa. METHODS: From August 1999 through May 2001, 643 HIV-1-negative women were recruited from family planning clinics in Orange Farm, South Africa. IPC [norethisterone enanthate (NET-EN) and depot medroxyprogesterone acetate (DMPA)] users and nonhormonal contraception users were recruited in approximately equal numbers. Eligible participants were seen at enrolment and on four follow-up visits over a 12-month period; 567 returned for at least one follow-up visit. Multivariable Poisson regression models with generalized estimating equations were used to compute the incidence rate ratios (IRRs) for infections with GC, CT, BV and TV by use of NET-EN or DMPA relative to nonuse during follow-up. RESULTS: In multivariable models, the use of DMPA slightly increased the risk of infection with CT [IRR=1.24; 95% confidence interval (95% CI)=0.80-1.94] and GC (IRR=1.30; 95% CI=0.58-2.98), although these associations were not statistically significant. In contrast, DMPA appeared to be protective for TV (IRR=0.35; 95% CI=0.12-1.01), although this estimate was very imprecise. The use of both DMPA and NET-EN was associated with a decreased risk of BV. CONCLUSIONS: The use of DMPA among women in this study population was associated with an increased - but not statistically significant - risk of cervical infection with chlamydia and gonorrhea, and a decreased risk of TV and BV. Given the inconsistencies and limitations of the data describing an increased risk of CT and GC with IPC use, the potential risk of sexually transmitted infections (STIs) must be balanced against the risk of unintended pregnancy and its health consequences, especially in developing countries. Women opting to use IPC should be counseled to use condoms to protect against STIs and HIV.
Authors: D A Eschenbach; S S Thwin; D L Patton; T M Hooton; A E Stapleton; K Agnew; C Winter; A Meier; W E Stamm Journal: Clin Infect Dis Date: 2000-06-13 Impact factor: 9.079
Authors: L C Ford; H A Hammill; R J DeLange; D A Bruckner; F Suzuki-Chavez; K L Mickus; T B Lebherz Journal: Am J Obstet Gynecol Date: 1987-05 Impact factor: 8.661
Authors: J M Baeten; P M Nyange; B A Richardson; L Lavreys; B Chohan; H L Martin; K Mandaliya; J O Ndinya-Achola; J J Bwayo; J K Kreiss Journal: Am J Obstet Gynecol Date: 2001-08 Impact factor: 8.661
Authors: Charles S Morrison; Patricia Bright; Emelita L Wong; Cynthia Kwok; Irina Yacobson; Charlotte A Gaydos; Heidi T Tucker; Paul D Blumenthal Journal: Sex Transm Dis Date: 2004-09 Impact factor: 2.830
Authors: Alison C Roxby; David N Fredricks; Katherine Odem-Davis; Kristjana Ásbjörnsdóttir; Linnet Masese; Tina L Fiedler; Stephen De Rosa; Walter Jaoko; James N Kiarie; Julie Overbaugh; R Scott McClelland Journal: J Acquir Immune Defic Syndr Date: 2016-04-01 Impact factor: 3.731
Authors: G Donders; G Bellen; D Janssens; B Van Bulck; P Hinoul; J Verguts Journal: Eur J Clin Microbiol Infect Dis Date: 2016-09-09 Impact factor: 3.267
Authors: J Paul Brooks; David J Edwards; Diana L Blithe; Jennifer M Fettweis; Myrna G Serrano; Nihar U Sheth; Jerome F Strauss; Gregory A Buck; Kimberly K Jefferson Journal: Contraception Date: 2016-11-29 Impact factor: 3.375
Authors: Amy Romer; Marcia L Shew; Susan Ofner; Melissa L Gilliam; Summer L Martins; J Dennis Fortenberry Journal: J Adolesc Health Date: 2012-06-05 Impact factor: 5.012
Authors: Bridget M Whitney; Sujatha Srinivasan; Kenneth Tapia; Eric Munene Muriuki; Bhavna H Chohan; Jacqueline M Wallis; Congzhou Liu; Brandon L Guthrie; R Scott McClelland; Noah G Hoffman; David N Fredricks; Alison C Roxby Journal: Clin Infect Dis Date: 2021-06-15 Impact factor: 9.079
Authors: Nicola Low; Matthew F Chersich; Kurt Schmidlin; Matthias Egger; Suzanna C Francis; Janneke H H M van de Wijgert; Richard J Hayes; Jared M Baeten; Joelle Brown; Sinead Delany-Moretlwe; Rupert Kaul; Nuala McGrath; Charles Morrison; Landon Myer; Marleen Temmerman; Ariane van der Straten; Deborah Watson-Jones; Marcel Zwahlen; Adriane Martin Hilber Journal: PLoS Med Date: 2011-02-15 Impact factor: 11.069
Authors: Léanie Kleynhans; Nelita Du Plessis; Gillian F Black; André G Loxton; Martin Kidd; Paul D van Helden; Gerhard Walzl; Katharina Ronacher Journal: PLoS One Date: 2011-09-08 Impact factor: 3.240